Axon Enterprise, Inc $AXON Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC lifted its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 10.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 36,275 shares of the biotechnology company’s stock after acquiring an additional 3,547 shares during the quarter. Rafferty Asset Management LLC’s holdings in Axon Enterprise were worth $26,032,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vestor Capital LLC boosted its stake in Axon Enterprise by 438,636.3% during the 2nd quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company’s stock valued at $690,170,000 after purchasing an additional 833,409 shares in the last quarter. Norges Bank acquired a new stake in shares of Axon Enterprise in the second quarter valued at $637,806,000. Vanguard Group Inc. boosted its stake in Axon Enterprise by 4.2% during the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after buying an additional 376,904 shares in the last quarter. Jennison Associates LLC boosted its stake in Axon Enterprise by 53.8% during the third quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after buying an additional 330,213 shares in the last quarter. Finally, 1832 Asset Management L.P. grew its holdings in Axon Enterprise by 129.2% during the second quarter. 1832 Asset Management L.P. now owns 536,420 shares of the biotechnology company’s stock worth $444,124,000 after acquiring an additional 302,420 shares during the period. Institutional investors own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on AXON shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a report on Monday, December 29th. Royal Bank Of Canada dropped their target price on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a report on Wednesday. Northcoast Research upgraded shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price for the company in a report on Tuesday, January 6th. Barclays decreased their price target on shares of Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Morgan Stanley dropped their price target on Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating on the stock in a report on Wednesday. Sixteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $762.93.

Insider Buying and Selling

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 1,797 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $539.23, for a total value of $968,996.31. Following the transaction, the insider owned 83,485 shares in the company, valued at approximately $45,017,616.55. This represents a 2.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Jennifer H. Mak sold 1,134 shares of Axon Enterprise stock in a transaction on Friday, December 19th. The shares were sold at an average price of $600.00, for a total transaction of $680,400.00. Following the sale, the chief accounting officer directly owned 13,740 shares of the company’s stock, valued at $8,244,000. This trade represents a 7.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 58,040 shares of company stock worth $32,251,738 over the last ninety days. 4.40% of the stock is currently owned by corporate insiders.

Axon Enterprise Price Performance

AXON opened at $542.40 on Friday. The firm has a market capitalization of $43.61 billion, a P/E ratio of 356.84, a PEG ratio of 16.34 and a beta of 1.48. The stock has a fifty day moving average of $537.92 and a 200-day moving average of $624.54. The company has a quick ratio of 2.89, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. Axon Enterprise, Inc has a 12-month low of $396.41 and a 12-month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The firm had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. During the same period in the previous year, the firm earned $2.08 earnings per share. Axon Enterprise’s quarterly revenue was up 38.5% on a year-over-year basis. Equities analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.